BACKGROUND: In SELECT (Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity), among 17 604 patients with known atherosclerotic cardiovascular disease and overweight or obesity, but not diabetes, randomization to the glucagon-like peptide-1 receptor agonist semaglutide significantly red...
Jorge Plutzky, P. Bogdański, H. Colhoun et al.· Circulation· 1 citation
BACKGROUND AND AIMS
In SELECT, subcutaneous semaglutide (target dose 2.4 mg) weekly in adults with pre-existing cardiovascular disease and body mass index ≥27 kg/m2 without diabetes significantly reduced major adverse cardiovascular events (MACE) by 20% vs placebo. This analysis explored potential mediators of this car...
H. Colhoun, A. Lincoff, D. Ryan et al.· European Heart Journal· 0 citations
Patients with T2DM, cardiovascular disease, and blood-based indices suggesting liver steatosis or fibrosis differed significantly with respect to the lipid profile, and an elevated HSI score, suggesting steatosis, was associated with dyslipidemia, and an elevated NFS score, suggesting fibrosis, was not.
Laura A M Konings, Weiwei Xu, Vivian D. de Jong et al.· Diabetology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
